Synmosa Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Synmosa Biopharma has a total shareholder equity of NT$8.1B and total debt of NT$2.4B, which brings its debt-to-equity ratio to 29%. Its total assets and total liabilities are NT$11.7B and NT$3.6B respectively. Synmosa Biopharma's EBIT is NT$616.8M making its interest coverage ratio 12.1. It has cash and short-term investments of NT$1.7B.
Key information
29.0%
Debt to equity ratio
NT$2.35b
Debt
| Interest coverage ratio | 12.1x |
| Cash | NT$1.65b |
| Equity | NT$8.10b |
| Total liabilities | NT$3.63b |
| Total assets | NT$11.73b |
Recent financial health updates
Recent updates
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?
Apr 04
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today
Mar 08Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 31Is Synmosa Biopharma (GTSM:4114) A Risky Investment?
Jan 05Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09
Financial Position Analysis
Short Term Liabilities: 4114's short term assets (NT$4.5B) exceed its short term liabilities (NT$2.1B).
Long Term Liabilities: 4114's short term assets (NT$4.5B) exceed its long term liabilities (NT$1.5B).
Debt to Equity History and Analysis
Debt Level: 4114's net debt to equity ratio (8.6%) is considered satisfactory.
Reducing Debt: 4114's debt to equity ratio has reduced from 53.8% to 29% over the past 5 years.
Debt Coverage: 4114's debt is well covered by operating cash flow (21.8%).
Interest Coverage: 4114's interest payments on its debt are well covered by EBIT (12.1x coverage).